Terms: = Colorectal cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
64 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
[TBL] [Abstract] [Full Text] [Related]
3. Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer.
Moench R; Gasser M; Nawalaniec K; Grimmig T; Ajay AK; de Souza LCR; Cao M; Luo Y; Hoegger P; Ribas CM; Ribas-Filho JM; Malafaia O; Lissner R; Hsiao LL; Waaga-Gasser AM
Oncotarget; 2022 Oct; 13():1140-1152. PubMed ID: 36264073
[TBL] [Abstract] [Full Text] [Related]
4. Human Colon cancer HT29 Cell Line treatment with High-Dose LAscorbic Acid Results to Reduced Angiogenic Proteins Expression and Elevated Pro-apoptotic Proteins Expression.
Samie KA; Dayer D; Eshkiki ZS
Curr Mol Med; 2023; 23(5):470-478. PubMed ID: 35713135
[TBL] [Abstract] [Full Text] [Related]
5. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
[TBL] [Abstract] [Full Text] [Related]
6. Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
Mehta R; Frakes J; Kim J; Nixon A; Liu Y; Howard L; Martinez Jimenez ME; Carballido E; Imanirad I; Sanchez J; Dessureault S; Xie H; Felder S; Sahin I; Hoffe S; Malafa M; Kim R
Oncologist; 2022 Aug; 27(8):621-e617. PubMed ID: 35325225
[TBL] [Abstract] [Full Text] [Related]
7. The dual role of microRNA-9 in gastrointestinal cancers: oncomiR or tumor suppressor?
Bahrami A; Jafari A; Ferns GA
Biomed Pharmacother; 2022 Jan; 145():112394. PubMed ID: 34781141
[TBL] [Abstract] [Full Text] [Related]
8. Donafenib: First Approval.
Keam SJ; Duggan S
Drugs; 2021 Nov; 81(16):1915-1920. PubMed ID: 34591285
[TBL] [Abstract] [Full Text] [Related]
9. Dysregulated pdgfr alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size.
Ben Jemii N; Tounsi-Kettiti H; Yaiche H; Mezghanni N; Jaballah Gabteni A; Fehri E; Ben Fayala C; Abdelhak S; Boubaker S
J Transl Med; 2020 Nov; 18(1):440. PubMed ID: 33213472
[TBL] [Abstract] [Full Text] [Related]
10. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5
Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R
Cell Death Dis; 2020 Oct; 11(10):916. PubMed ID: 33099574
[TBL] [Abstract] [Full Text] [Related]
11. Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
Ettrich TJ; Perkhofer L; Decker T; Hofheinz RD; Heinemann V; Hoffmann T; Hebart HF; Herrmann T; Hannig CV; Büchner-Steudel P; Güthle M; Hermann PC; Berger AW; Seufferlein T
Int J Cancer; 2021 Mar; 148(6):1428-1437. PubMed ID: 32930387
[TBL] [Abstract] [Full Text] [Related]
12. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Zhou Y; Zhang X; Wu X; Zhou Y; Zhang B; Liu X; Wu X; Li Y; Shen L; Li J
Cancer Med; 2020 Sep; 9(17):6225-6233. PubMed ID: 32677196
[TBL] [Abstract] [Full Text] [Related]
13. PAI1 is a Marker of Bad Prognosis in Rectal cancer but Predicts a Better Response to treatment with PIM Inhibitor AZD1208.
Muñoz-Galván S; Rivero M; Peinado-Serrano J; Martinez-Pérez J; Fernández-Fernández MC; Ortiz MJ; García-Heredia JM; Carnero A
Cells; 2020 Apr; 9(5):. PubMed ID: 32344898
[TBL] [Abstract] [Full Text] [Related]
14. Case report of ascending colon cancer and multiple jejunal GISTs in a patient with neurofibromatosis type 1 (NF1).
Shang L; Fang Z; Liu J; Du F; Jing H; Xu Y; Dong K; Zhang X; Wu H; Jing C; Li L
BMC Cancer; 2019 Dec; 19(1):1196. PubMed ID: 31805970
[TBL] [Abstract] [Full Text] [Related]
15. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2018; 211():45-56. PubMed ID: 30069758
[TBL] [Abstract] [Full Text] [Related]
16. Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
Riesco-Martinez MC; Sanchez-Torre A; Garcia-Carbonero R
Expert Opin Investig Drugs; 2017 Nov; 26(11):1295-1305. PubMed ID: 28965421
[TBL] [Abstract] [Full Text] [Related]
17. The potential role of nintedanib in treating colorectal cancer.
Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
[TBL] [Abstract] [Full Text] [Related]
18. The Role of PDGFs and pdgfrs in colorectal cancer.
Manzat Saplacan RM; Balacescu L; Gherman C; Chira RI; Craiu A; Mircea PA; Lisencu C; Balacescu O
Mediators Inflamm; 2017; 2017():4708076. PubMed ID: 28163397
[No Abstract] [Full Text] [Related]
19. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
Schiffmann LM; Brunold M; Liwschitz M; Goede V; Loges S; Wroblewski M; Quaas A; Alakus H; Stippel D; Bruns CJ; Hallek M; Kashkar H; Hacker UT; Coutelle O
Br J Cancer; 2017 Feb; 116(5):600-608. PubMed ID: 28141797
[TBL] [Abstract] [Full Text] [Related]
20. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.
Zhou Y; Shan S; Li ZB; Xin LJ; Pan DS; Yang QJ; Liu YP; Yue XP; Liu XR; Gao JZ; Zhang JW; Ning ZQ; Lu XP
Cancer Sci; 2017 Mar; 108(3):469-477. PubMed ID: 28004478
[TBL] [Abstract] [Full Text] [Related]
[Next]
